Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Colchicine in Moderate Symptomatic COVID-19 Patients (COLCOVIDBD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04527562
Recruitment Status : Completed
First Posted : August 26, 2020
Last Update Posted : January 11, 2021
Sponsor:
Information provided by (Responsible Party):
Dr. Md. Motlabur Rahman, Dhaka Medical College

Brief Summary:
This is a prospective, double blind, randomized, placebo controlled clinical trial. The participants will be randomized into two groups (group A and group B). Patients of group-A are the treatment group. They will be treated with optimal treatment based on the algorithm proposed in National Guidelines on Clinical Management of Coronavirus Disease 2019 (Covid-19) Version 7.0, 28 May 2020, along with Colchicine for 14 days. The patients in group-B will be controlled group. They will be treated with optimal treatment based on the algorithm proposed in National Guideline along with a placebo.

Condition or disease Intervention/treatment Phase
Covid19 Drug: Colchicine Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 299 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy
Actual Study Start Date : July 14, 2020
Actual Primary Completion Date : November 15, 2020
Actual Study Completion Date : December 10, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Colchicine

Arm Intervention/treatment
Active Comparator: TRAETMENT GROUP
Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
Drug: Colchicine
Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.

Placebo Comparator: CONTROL /PLACEBO GROUP

COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo.

Standard care of enrolled study patients will consist:

  1. Isolation facility
  2. Symptomatic treatment with Paracetamol, Fexofenadine
  3. Steam inhalation/Gurgle of Lukewarm water.
  4. Ensuring of hand wash (20 seconds each time) and ideally wearing mask.
  5. Monitoring by the attending nurses.
Drug: Placebo
Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.




Primary Outcome Measures :
  1. Time to develop clinical deterioration, defined as the time from randomization to a deterioration of two points (from the status at randomization) on a Seven-category ordinal scale. [ Time Frame: 14 days following randomization ]
    Seven-category ordinal scale. The scale is recommended by the WHO R&D Blueprint expert group. The seven-category ordinal scale consisted of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilation, or both; and 7, death


Secondary Outcome Measures :
  1. Length of hospital stay [ Time Frame: 14 days following randomization ]
    Days from date of enrollment to date of discharge

  2. Number of participant requiring increased amount of supplemental oxygen [ Time Frame: 14 days following randomization ]
    Proportion of participants who required oxygen supplementation

  3. Number of participants requiring mechanical ventilation [ Time Frame: 14 days following randomization ]
    Proportion of participants who required mechanical ventilation

  4. Number of participants who die [ Time Frame: 14 days following randomization ]
    Proportion of participants who die from any cause



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Males and females of least 18 years of age and can swallow tablets
  • Competent and willing to provide informed consent
  • Patient must have received a diagnosis of COVID-19 infection with positive RT-PCR for SARS CoV-2 within the last 3 days
  • Patients with moderate symptoms (According to National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID- 19).Version 7.0 .2020, DGHS, MOHFW, Government of the People's Republic of Bangladesh). Following features of moderate covid-19 must be present-

    1. Fever or history of fever
    2. Cough and /or Shortness of breath
    3. Oxygen saturation 94% or more
    4. Pneumonia -pulmonary consolidations on chest imaging (chest x ray or CT scan of chest) involving less than 50%of lungs
    5. CRB 65 score 0

Exclusion criteria:

  • Pregnancy and breast-feeding
  • Known hypersensitivity to colchicine
  • Known chronic illness e.g hepatic failure, chronic kidney disease (eGFR<30ml/min), decompensated heart failure, long QT syndrome (QTc >450 msec.)
  • Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption
  • Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout)
  • Patient undergoing chemotherapy for cancer
  • Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04527562


Locations
Layout table for location information
Bangladesh
Dhaka Medical College Hospital
Dhaka-1000, Bangladesh
Sponsors and Collaborators
Dhaka Medical College
Investigators
Layout table for investigator information
Study Chair: Mujibur Rahman, MBBS,MD,FCPS Professor and Head, Department of Medicine
Principal Investigator: Motlabur Rahman, MBBS, FCPS,FACP Associate Professor, Department of Medicine
Layout table for additonal information
Responsible Party: Dr. Md. Motlabur Rahman, Associate Professor, Department of Medicine, Dhaka Medical College
ClinicalTrials.gov Identifier: NCT04527562    
Other Study ID Numbers: U1111-1255-3541
First Posted: August 26, 2020    Key Record Dates
Last Update Posted: January 11, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Dr. Md. Motlabur Rahman, Dhaka Medical College:
Covid 19
Colchicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Colchicine
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents